PAFP Provider Feedback Trial in Nepal
Launched by MARIE STOPES INTERNATIONAL · Mar 3, 2017
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
The overall goal of the proposed research project is to increase uptake of long-acting reversible contraceptives (LARCs) among clients who receive a safe abortion at a Marie Stopes International - Nepal (MSI-N)/ Sunaulo Parivar Nepal (SPN) centre using a behaviourally-informed intervention: monthly feedback to service providers comparing their LARC uptake as a percentage of PAFP uptake performance to other centres. The impact of the intervention will be evaluated using a clustered, stepped wedge randomized controlled trial (RCT). The intervention will be implemented and data will be collect...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • All women over the age of 18 who receive safe abortion services at the 36 centres are eligible to participate in the study. Women will be opted in to the study.
- Exclusion Criteria:
- • Women \<18
About Marie Stopes International
Marie Stopes International (MSI) is a leading global nonprofit organization dedicated to ensuring access to safe and effective reproductive health services, including family planning and abortion care. Operating in over 37 countries, MSI focuses on empowering individuals to make informed choices about their reproductive health while advocating for gender equality and improved health outcomes. Through innovative programs and partnerships, MSI conducts clinical trials and research to advance reproductive health practices and contribute to evidence-based policies, ultimately aiming to enhance the quality of life for women and families worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kathmandu, Bagati, Nepal
Kathmandu, Bagati, Nepal
Kathmandu, Bagmati, Nepal
Kathmandu, Bagmati, Nepal
Kavre, Bagmati, Nepal
Nuwakot, Bagmati, Nepal
Banke, Bheri, Nepal
Surkhet, Bheri, Nepal
Parbat, Dhaulagiri, Nepal
Gorkha, Gandaki, Nepal
Kaski, Gandaki, Nepal
Tanahun, Gandaki, Nepal
Dhanusa, Janakpur, Nepal
Mahottari, Janakpur, Nepal
Sarlahi, Janakpur, Nepal
Jumla, Karnali, Nepal
Dhankuta, Koshi, Nepal
Morang, Koshi, Nepal
Sunsari, Koshi, Nepal
Arghakhachi, Lumbini, Nepal
Gulmi, Lumbini, Nepal
Kapilbastu, Lumbini, Nepal
Kapilbastu, Lumbini, Nepal
Nawalparasi, Lumbini, Nepal
Rupandehi, Lumbini, Nepal
Rupandehi, Lumbini, Nepal
Dadheldhura, Mahakali, Nepal
Ilam, Mechi, Nepal
Jhapa, Mechi, Nepal
Chitwan, Narayani, Nepal
Makwanpur, Narayani, Nepal
Parsa, Narayani, Nepal
Dang, Rapti, Nepal
Pyuthan, Rapti, Nepal
Siraha, Sagarmatha, Nepal
Kailali, Seti, Nepal
Patients applied
Trial Officials
Saugato Datta
Principal Investigator
Ideas42
Karina Lorenzana
Principal Investigator
Ideas42
Pragya Gartoulla, PhD
Principal Investigator
Marie Stopes Nepal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials